Sarepta Therapeutics (SRPT)

[r clarke]

SRPT sells voucher for $125M, but is this a positive or negative going forward?



Sarepta Therapeutics Agrees to Sale of Priority Review Voucher for $125M
Tuesday 02/21/2017 07:00 AM ET - BusinessWire via Dow Jones News
-- Sale of PRV Provides a Significant Infusion of Non-Dilutive Capital -- CAMBRIDGE, Mass.--(BUSINESS WIRE)--February 21, 2017-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, today announced it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV). Sarepta received the PRV when EXONDYS 51(TM) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with Duchenne muscular dystrophy amenable to exon 51 skipping.